close

Agreements

Date: 2013-10-31

Type of information: Commercialisation agreement

Compound: Oralair®

Company: Stallergenes (France) Greer Laboratories (USA)

Therapeutic area: Allergic diseases - Immunological diseases

Type agreement:

commercialisation

Action mechanism:

Oralair® is an allergen immunotherapy sublingual tablet consisting of five purified and calibrated pollen extracts: Perennial Ryegrass (Lolium perenne), Kentucky Bluegrass (Poa pratensis), Timothy Grass (Phleum pratense), Orchard Grass (Dactylis glomerata) and Sweet Vernal Grass (Anthoxanthum odoratum). To date, Oralair is available in 16 European countries and also continues to expand beyond Europe: following a positive start in Australia/New Zealand and Russia, the product was launched a few months ago in Canada, which makes it the first allergen immunotherapy tablet to be registered and marketed in North America.

Disease: grass allergy

Details:

* On October 31, 2013, Stallergenes and Greer® Laboratories have signed an exclusive agreement for the United States commercialization rights to Oralair®, an investigational grass allergy immunotherapy tablet currently under review by the FDA.
Oralair® is a grass pollen sublingual immunotherapy tablet that includes five grasses (sweet vernal grass, orchard grass, perennial rye grass, timothy grass, and Kentucky bluegrass) and is being investigated for the treatment of grass pollen-induced allergic rhinitis or conjunctivitis in adults and children aged 5 and older.

Financial terms:

Under the terms of the agreement, Greer will lead the sales and marketing efforts for Oralair® in the United States and Stallergenes will be responsible for tablet production and supply. Stallergenes will receive regulatory and commercial milestone payments totalling up to $120 million, plus royalties and a transfer price.

Latest news:

Is general: Yes